Weller M - Search Results

1

Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?

Streffer JR, Schuster M, Zipp F, Weller M. Streffer JR, et al. Among authors: weller m. J Neurooncol. 1998 Dec;40(3):233-5. doi: 10.1023/a:1006173019048. J Neurooncol. 1998. PMID: 10066095

2

Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma.

Weller M, Stevens A, Sommer N, Wiethölter H. Weller M, et al. J Neurooncol. 1993 Apr;16(1):55-9. doi: 10.1007/BF01324835. J Neurooncol. 1993. PMID: 8410143

3

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Weller M, Fontana A. Weller M, et al. Brain Res Brain Res Rev. 1995 Sep;21(2):128-51. doi: 10.1016/0165-0173(95)00010-0. Brain Res Brain Res Rev. 1995. PMID: 8866671 Review.

4

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.

Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M. Roth W, et al. Among authors: weller m. Cancer Immunol Immunother. 1997 Mar;44(1):55-63. doi: 10.1007/s002620050355. Cancer Immunol Immunother. 1997. PMID: 9111585 Free PMC article.

5

Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells.

Wagenknecht B, Gulbins E, Lang F, Dichgans J, Weller M. Wagenknecht B, et al. Among authors: weller m. FEBS Lett. 1997 Jun 2;409(1):17-23. doi: 10.1016/s0014-5793(97)00468-7. FEBS Lett. 1997. PMID: 9199495 Free article.

6

Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand.

Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M. Zipp F, et al. Among authors: weller m. J Immunol. 1997 Sep 1;159(5):2108-15. J Immunol. 1997. PMID: 9278296

7

Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.

Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Weller M, et al. Int J Cancer. 1997 Nov 27;73(5):707-14. doi: 10.1002/(sici)1097-0215(19971127)73:5<707::aid-ijc16>3.0.co;2-2. Int J Cancer. 1997. PMID: 9398050

8

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis.

Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Zipp F, et al. Among authors: weller m. Ann Neurol. 1998 Jan;43(1):116-20. doi: 10.1002/ana.410430120. Ann Neurol. 1998. PMID: 9450777

9

Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.

Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M. Roth W, et al. Among authors: weller m. Br J Cancer. 1998;77(3):404-11. doi: 10.1038/bjc.1998.64. Br J Cancer. 1998. PMID: 9472635 Free PMC article.

10

CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2.

Zipp F, Faber E, Sommer N, Müller C, Dichgans J, Krammer PH, Martin R, Weller M. Zipp F, et al. Among authors: weller m. J Neuroimmunol. 1998 Jan;81(1-2):168-72. doi: 10.1016/s0165-5728(97)00173-2. J Neuroimmunol. 1998. PMID: 9521618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,712 results

Search Page

Filters